Published in Lancet on July 04, 1964
Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1. Proc Natl Acad Sci U S A (2007) 4.62
Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. J Clin Invest (1967) 3.60
The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev (2008) 2.73
Characterization of the responses of circulating glucagon-like immunoreactivity to intraduodenal and intravenous administration of glucose. J Clin Invest (1968) 2.46
GIP and GLP-1, the two incretin hormones: Similarities and differences. J Diabetes Investig (2010) 2.40
Insulin secretion in response to protein ingestion. J Clin Invest (1966) 1.65
Regulation of lactating-rat mammary-gland lipogenesis by insulin and glucagon in vivo. The role and site of action of insulin in the transition to the starved state. Biochem J (1984) 1.59
Attenuated GLP-1 secretion in obesity: cause or consequence? Gut (1996) 1.55
Targeting the CNS to treat type 2 diabetes. Nat Rev Drug Discov (2009) 1.45
Effects of secretin, pancreozymin, or gastrin on the response of the endocrine pancreas to administration of glucose or arginine in man. J Clin Invest (1969) 1.42
Taste signaling elements expressed in gut enteroendocrine cells regulate nutrient-responsive secretion of gut hormones. Am J Clin Nutr (2009) 1.34
The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology (2008) 1.26
Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels. J Clin Invest (1978) 1.22
Non-nutritive sweeteners, energy balance, and glucose homeostasis. Curr Opin Clin Nutr Metab Care (2011) 1.21
Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2012) 1.20
Mechanisms of glucose homeostasis after Roux-en-Y gastric bypass surgery in the obese, insulin-resistant Zucker rat. Ann Surg (2009) 1.20
Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Endocr Rev (2008) 1.18
A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf (2012) 1.17
Intestinal hormones and plasma insulin: an insulinotropic action of secretin. Br Med J (1967) 1.16
The effect of gastrin on basal- and glucose-stimulated insulin secretion in man. J Clin Invest (1973) 1.16
The gastrointestinal stimulus to insulin release. II. A dual action of secretin. J Clin Invest (1970) 1.13
Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp Diabetes Res (2011) 1.12
Taste cells of the gut and gastrointestinal chemosensation. Mol Interv (2008) 1.11
The structure and function of the glucagon-like peptide-1 receptor and its ligands. Br J Pharmacol (2012) 1.10
Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. Drug Healthc Patient Saf (2010) 1.10
Carbohydrate metabolism in duodenal ulcer patients. Gut (1967) 1.07
Gastrectomy induces impaired insulin and glucagon secretion: evidence for a gastro-insular axis in mice. J Physiol (1999) 1.05
GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states. Diabetes (2012) 1.03
Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor. Exp Diabetes Res (2012) 0.99
Suppressive effect of secretin upon pancreatic alpha cell function. J Clin Invest (1972) 0.97
Nerveless and gutsy: intestinal nutrient sensing from invertebrates to humans. Semin Cell Dev Biol (2012) 0.97
Glucose-galactose malabsorption. Arch Dis Child (1967) 0.94
Glucose transporters are expressed in taste receptor cells. J Anat (2011) 0.94
Incretin-based drugs for type 2 diabetes: Focus on East Asian perspectives. J Diabetes Investig (2016) 0.92
Metabolic effects of non-nutritive sweeteners. Physiol Behav (2015) 0.92
Glucose tolerance and insulin secretion in patients with chronic duodenal ulcer. Br Med J (1972) 0.90
Hormonal control of pancreatic endocrine and exocrine secretion. Gut (1972) 0.90
Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose. Annu Rev Nutr (2014) 0.89
Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists. Cardiovasc Diabetol (2014) 0.88
The gut and oral glucose tolerance. Gut (1969) 0.88
Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation. Br J Pharmacol (2014) 0.88
Effect of duodenectomy on gastric motility and gastric hormones in dogs. Ann Surg (2001) 0.87
Methods and models for metabolic assessment in mice. J Diabetes Res (2013) 0.86
Incretin hormones as immunomodulators of atherosclerosis. Front Endocrinol (Lausanne) (2012) 0.86
CNS GLP-1 regulation of peripheral glucose homeostasis. Physiol Behav (2008) 0.86
Regulation of pancreatic endocrine function by gastrointestinal hormones. Proc R Soc Med (1968) 0.85
Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus. Open Med Chem J (2011) 0.84
Effect of massive bowel resection on enteroinsular axis. Gut (1979) 0.84
Investigating G protein signalling bias at the glucagon-like peptide-1 receptor in yeast. Br J Pharmacol (2014) 0.84
The Involvement of the T1R3 Receptor Protein in the Control of Glucose Metabolism in Mice at Different Levels of Glycemia. J Evol Biochem Physiol (2014) 0.83
Is the GLP-1 system a viable therapeutic target for weight reduction? Rev Endocr Metab Disord (2011) 0.83
Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. Ther Clin Risk Manag (2009) 0.83
Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties. Diabetol Metab Syndr (2014) 0.82
Physiological role for cholecystokinin in reducing postprandial hyperglycemia in humans. J Clin Invest (1988) 0.82
Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective. J Nutr Metab (2012) 0.81
The Incretins and Pancreatic beta-Cells: Use of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide to Cure Type 2 Diabetes Mellitus. Korean Diabetes J (2010) 0.81
Insulinotropic action of secretin. Br Med J (1967) 0.80
Pancreatic beta-cell signaling: toward better understanding of diabetes and its treatment. Proc Jpn Acad Ser B Phys Biol Sci (2010) 0.79
Insulin response to carbohydrate ingestion after gastric surgery with special reference to hypoglycaemia. Gut (1969) 0.79
The enteroinsular axis. J Clin Pathol Suppl (Assoc Clin Pathol) (1978) 0.79
Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes. Pharmacol Rev (2016) 0.78
Impaired Glucose Metabolism in Mice Lacking the Tas1r3 Taste Receptor Gene. PLoS One (2015) 0.78
Specific biologic effects of intestinal glucagon-like materials. J Clin Invest (1973) 0.78
The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class? J Diabetes Res (2015) 0.78
Glucose tolerance and serum insulin in the unaffected first-degree relatives of diabetics. Br Med J (1967) 0.78
Diabetes management and hypoglycemia in safety sensitive jobs. Saf Health Work (2011) 0.78
Truncated Glucagon-like Peptide-1 and Exendin-4 α-Conotoxin pl14a Peptide Chimeras Maintain Potency and α-Helicity and Reveal Interactions Vital for cAMP Signaling in Vitro. J Biol Chem (2016) 0.77
Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives. Ther Clin Risk Manag (2015) 0.77
Enteroendocrine cells are specifically marked by cell surface expression of claudin-4 in mouse small intestine. PLoS One (2014) 0.77
A case-control analysis of common variants in GIP with type 2 diabetes and related biochemical parameters in a South Indian population. BMC Med Genet (2010) 0.77
Lixisenatide as add-on therapy to basal insulin. Drug Des Devel Ther (2013) 0.76
Impaired enteroendocrine development in intestinal-specific Islet1 mouse mutants causes impaired glucose homeostasis. Am J Physiol Gastrointest Liver Physiol (2014) 0.76
Nutrition and L and K-enteroendocrine cells. Curr Opin Endocrinol Diabetes Obes (2011) 0.76
Present and Prospective Pharmacotherapy for the Management of Patients with Type 2 Diabetes. Clin Med Ther (2009) 0.75
Oral glucose decreases hepatic extraction of insulin. Br Med J (Clin Res Ed) (1983) 0.75
Plasma insulin response to oral carbohydrate in patients with glucose and lactose malabsorption. Gut (1970) 0.75
Incretins and the intensivist: what are they and what does an intensivist need to know about them? Crit Care (2014) 0.75
The pancreas and diabetes mellitus. Postgrad Med J (1967) 0.75
Osteocalcin and the Regulation of Glucose Metabolism. Clin Rev Bone Miner Metab (2013) 0.75
No effect of glucose administration in a novel contextual fear generalization protocol in rats. Transl Psychiatry (2016) 0.75
Patterns of insulin secretion in man. Proc R Soc Med (1974) 0.75
Is endogenous GLP-1 the only important enhancer of glucose-induced insulin secretion in type 2 diabetes? Diabetes (2012) 0.75
Relief of diabetes by duodenal-jejunal bypass sleeve implantation in the high-fat diet and streptozotocin-induced diabetic rat model is associated with an increase in GLP-1 levels and the number of GLP-1-positive cells. Exp Ther Med (2015) 0.75
Exenatide Use in the Management of Type 2 Diabetes Mellitus. Pharmaceuticals (Basel) (2010) 0.75
Gastric inhibitory polypeptide (GIP). J Clin Pathol Suppl (Assoc Clin Pathol) (1978) 0.75
Eulogy for the Metabolic Clinical Investigator? Diabetes (2016) 0.75
No Association of Proton Pump Inhibitor Use with Fasting or Postload Glycaemia in Patients with Cardiovascular Disease: A Cross-Sectional Retrospective Study. Int J Med Sci (2017) 0.75
Effect of motilin on endogenous release of insulin in conscious dogs in the fed state. Dig Dis Sci (2003) 0.75
Incretin Secretion in Humans is under the Influence of Cannabinoid Receptors. Am J Physiol Endocrinol Metab (2017) 0.75
THE ABSORPTION OF MONOSACCHARIDES IN MAN. Clin Sci (1964) 2.35
Hepatitis caused by the newer amine-oxidase-inhibiting drugs. Lancet (1961) 1.69
ABSORPTION OF SHORT CHAIN FATTY ACIDS IN MAN. Proc Soc Exp Biol Med (1964) 1.58
ULCERATIVE COLITIS IN CHRONIC LIVER DISEASE. Q J Med (1965) 1.26
SIDEROBLASTIC ANAEMIA IN ADULT COELIAC DISEASE. Gut (1964) 1.11
ABSORPTION OF FRUCTOSE IN MAN. Proc Soc Exp Biol Med (1965) 1.06
Changes in the histochemical appearances of cholinesterase at the motor and plate following denervation. Br J Exp Pathol (1956) 0.94
AN ASSESSMENT OF THE DIAGNOSTIC AND PROGNOSTIC VALUE OF SERUM VITAMIN B12 LEVELS IN LIVER DISEASE. Gut (1964) 0.93
Importance of the egg shell of Ascaridia galli to the infectivity of its larva. J Parasitol (1956) 0.92
Effect of denervation on the histochemical appearance of cholinesterase at the myoneural junction. Nature (1955) 0.78
ULCERATIVE COLITIS AND CIRRHOSIS OF THE LIVER. Proc R Soc Med (1964) 0.75
Thrombotic thrombocytopenic purpura in pregnancy. JAMA (1963) 0.75